Progestogen for treating threatened miscarriage

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Wahabi, Hayfaa A ^a   Abed Althagafi, N F ^b   Elawad, M ^b  

^a KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

^b NONE

Author keywords

Abortion, threatened *drug therapy ; Female; Humans; Pregnancy; Progestins *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

GESTAGEN; PLACEBO; PROGESTERONE;

ABDOMINAL PAIN; ANALGESIA; CHILD HEALTH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DEPRESSION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; EMBASE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPOSPADIAS; MATERNAL WELFARE; MEDLINE; META ANALYSIS; MORTALITY; NIDATION; PREGNANCY; PROGESTERONE RELEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SHOCK; SPONTANEOUS ABORTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TERATOGENICITY; UTERINE CERVIX; UTERUS; VAGINA BLEEDING;

EID: 44949153572     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005943.pub2     Document Type: Review

References (66)

1. Gerhard 1987 {published data only} Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biological Research in Pregnancy and Perinatology 1987;8:26-34.
2. Palagiano 2004 {published data only} Palagiano A, Bulletti C, Pace MC, De Ziegler D, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Annals of the New York Academy of Sciences 2004;1034:200-10.
3. Berle 1977 Berle P, Behnke K. The treatment of threatened abortion. Geburtshilfe und Frauenheilkunde 1977;37:139-42.
4. Berle 1980 Berle P, Budenz M, Michaelis J. Is hormonal therapy still justified in imminent abortion. Zeitschrift fur Geburtshilfe und Perinatologie 1980;184:353-8.
5. Brenner 1962 Brenner WE, Hendricks CH. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. American Journal of Obstetrics and Gynecology 1962;83:1094-8.
6. Check 1995 Check JH, Tarquini P, Gandy P, Lauer C. A randomized study comparing the efficacy of reducing the spontaneous abortion rate following lymphocyte immunotherapy and progesterone treatment vs progesterone alone in primary habitual aborters. Gynecologic and Obstetric Investigation 1995;39:257-61.
7. Corrado 2002 Corrado F, Dugo C, Cannata ML, Di Bartolo M, Scilipoti A, Stella NC. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. European Journal of Obstetrics & Gynecology and Reproductive Biology 2002;100:196-8.
8. Crowder 1950 Crowder RE, Bills ES, Broadbent JS. The management of threatened abortion: a study of 100 cases. American Journal of Obstetrics and Gynecology 1950;60:896-9.
9. El Zibdeh 2000 El Zibdeh MY. Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility 2000;70(3 Suppl 1):S77-S78.
10. El Zibdeh 2002 El Zibdeh M. Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin [abstract]. 10th World Congress on Menopause; 2002 July 10-14; Berlin, Germany. 2002:136.
11. El Zibdeh 2005 El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry & Molecular Biology 2005;97(5):431-4.
12. Fuchs 1966 Fuchs F, Olsen P. An attempted double-blind controlled trial of progesterone therapy in habitual abortion. Ugeskrift for Laeger 1966;128:1461-2.
13. G-Videtzky 1965 Govaerts-Videtzky M, Martin L, Hubinont PO. A double-blind study of progestogen treatment in spontaneous abortion (preliminary report). Journal of Obstetrics and Gynaecology of the British Commonwealth 1965;72:1034.
14. Goldzieher 1964 Goldzieher JW. Double-blind trial of a progestin in habitual abortion. JAMA 1964;188(7):651-4.
15. Johnson 1975 Johnson JWC, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine 1975;293:675-80.
16. Klopper 1965 Klopper AI, MacNaughton MC. Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth 1965;72:1022-8.
17. Le Vine 1964 Le Vine L. Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery 1964;72:30-6.
18. Luz 1988 Luz NP. Hormones in the treatment of patients with threatened early pregnancy loss. Personal communication 1988.
19. Moller 1965 Moller KJA, Fuchs F. Double blind controlled trial of 6-methyl-17-acetoxyprogesterone in threatened abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth 1965;72:1042-4.
20. Nyboe 2002 Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, et al.Progesterone supplementation during early gestations after ivf or icsi has no effect on the delivery rates: a randomized controlled trial. Human Reproduction 2002;17(2):357-61.
21. Omar 2005 Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. Journal of Steroid Biochemistry & Molecular Biology 2005;97(5):421-5.
22. Prietl 1992 Prietl G, Diedrich K, Van der Ven HH, Luckhaus J, Krebs D. The effect of 17alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial. Human Reproduction 1992;7(1):1-5.
23. Reijnders 1988 Reijnders FJL, Thomas CMG, Doesburg WH, Rolland R, Eskes TKAB. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. British Journal of Obstetrics and Gynaecology 1988;95:462-8.
24. Shearman 1963 Shearman RP, Garrett WJ. Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. BMJ 1963;1:292-5.
25. Smitz 1992 Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. Randomized prospective trial comparing supplementation of the luteal phase and of early pregnancy by natural progesterone given by intramuscular or vaginal administration. Revue Francaise de Gynecologie et d Obstetrique 1992;87:507-16.
26. Sondergaard 1985 Sondergaard F, Ottesen B, Detlefsen GU, Schierup L, Pederson SC, Lebech PE. Progesterone treatment of cases of threatened pre-term delivery in women with a low level of plasma progesterone. Contraception Fertilite Sexualite 1985;13:1227-31.
27. Souka 1980 Souka AR, Osman M, Sibaie F, Einen MA. Therapeutic value of indomethacin in threatened abortion. Prostaglandins 1980;19:457-60.
28. Swyer 1953 Swyer GIM, Daley D. Progesterone implantation in habitual abortion. BMJ 1953;1:1073-86.
29. Tognoni 1980 Tognoni G, Ferrario L, Inzalaco M, Crosignani PG. Progestagens in threatened abortion. Lancet 1980;2:1242-3.
30. Turner 1966 Turner SJ, Mizock GB, Feldman GL. Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. American Journal of Obstetrics and Gynecology 1966;95:222-7.
31. Zhang 2000 Zhang J, Zhang Y, Liu G. Clinical and experimental study on yun'an granule in treating threatened abortion. Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 2000;20(4):251-4.
32. Brigham 1999 Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Human Reproduction 1999;14:2868-71.
33. Burgoyne 1991 Burgoyne PS, Holland K, Stephens R. Incidence of numerical chromosome anomalies in human pregnancy estimated from induced and spontaneous abortion data. Human Reproduction 1991;6(4):555-65.
34. CE 1998 Lewis G, Drife J, Botting B, Gordon G, Greer I, Kumar C, et al.Why mothers die. Report on confidential inquiries into maternal death in the United Kingdom 1994-6. London: HMSO, 1998.
35. Cunningham 2001a Cunningham FG. Section IX. Reproductive success and failure. Williams obstetrics. 21st Edition. New York: McGraw-Hill, 2001.
36. Cunningham 2001b Cunningham FG, editor(s). Physiology of pregnancy. Williams obstetrics. 21st Edition. New York: McGraw-Hill, 2001.
37. Di Renzo 2005 Di Renzo GC, Rosati A, Mattei A, Gojinic M, Gerli S. The changing role of progesterone in preterm labour. BJOG: an international journal of obstetrics and gynaecology 2005;112 Suppl 1:57-60.
38. Dodd 2006 Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 1.Art. No.: CD004947. DOI:10.1002/14651858.CD004947.pub2.
39. Dudas 2006 Dudas I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenital Anomalies 2006;46(4):194-8.
40. Dyregrove 1987 Dyregrove A, Mathieson SB. Stillbirth, neonatal death and SIDS: parental reactions. Scandinavian Journal of Psychology 1987;28:104-14.
41. Everett 1997 Everett C. Incident and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997;315:32-4.
42. Falco 1996 Falco P, Milano V, Pilu G, David C, Grisolia G, Rizzo N, et al.Sonography of pregnancies with first- trimester bleeding and a viable embryo: a study of prognostic indicators by logistic regression analysis. Ultrasound in Obstetrics and Gynecology 1996;7:165-9.
43. Gates 2005 Gates S. Methodological Guidelines. In: the Editorial team. Pregnancy and Childbirth Group. About The Cochrane Collaboration (Collaborative Review Groups (CRGs) 2005, Issue 2.
44. Goyaux 2001 Goyaux N, Alihonou E, Diadhiou F, Thonneau PF. Complications of induced abortion and miscarriage in three African countries: a hospital-based study among WHO collaborating centers. Acta Obstetricia et Gynecologica Scandinavica 2001;80:568-73.
45. Greene 1999 Greene MF. Spontaneous abortion and major malformations in women with diabetes mellitus. Seminars in Reproductive Endocrinology 1999;17:127-36.
46. Hemminki 1998 Hemminki E. Treatment of miscarriage: current practice and rationale. Obstetrics & Gynecology 1998;91(2): 247-53.
47. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
48. Huisjes 1984 Huisjes HJ. Spontaneous abortion. London: Churchill Livingstone, 1984.
49. Kalinka 2005 Kalinka J, Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. American Journal of Reproductive Immunology 2005;53:166-71.
50. Katz 1985 Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstetrics & Gynecology 1985;65(6):775-80.
51. Lede 2005 Lede R, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database of Systematic Reviews 2005, Issue 3.Art. No.: CD002857. DOI:10.1002/14651858.CD002857.pub2.
52. Makrydimas 2003 Makrydimas G, Sebire NJ, Lolis D, Vlassis N, Nicolaides KH. Fetal loss following ultrasound diagnosis of a live fetus at 6-10 weeks of gestation. Ultrasound in Obstetrics and Gynecology 2003;22:368-72.
53. McBride 1991 McBride WZ. Spontaneous abortion. American Family Physician 1991;43:175-82.
54. Meis 2004 Meis PJ, Connors N. Progesterone treatment to prevent pre-term birth. Clinical Obstetrics and Gynecology 2004;47:784-95.
55. Nielsen 1999 Nielsen S, Hahlin M, Platz-Christensen J. Randomised trial comparing expectant with medical management for first trimester miscarriage. British Journal of Obstetrics and Gynaecology 1999;106:804-7.
56. Oates-Whitehead 2003 Oates-Whitehead RM, Hass DM, Carrier JAK. Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD003511. DOI:10.1002/14651858.CD003511.
57. Olson 2005 Olson CK, Keppler-Noreuil KM, Romitti PA, Budelier WT, Ryan G, Sparks AE, et al.In vitro fertilization is associated with an increase in major birth defects. Fertility and Sterility 2005;84(5):1308- 15.
58. Owen 2004 Owen J, Yost N, Berghella V, MacPherson C, Swain M, Dildy GA 3rd, et al.Can shortened midtrimester cervical length predict very early spontaneous preterm birth?. American Journal of Obstetrics and Gynecology 2004;191(1):298-303.
59. RevMan 2003 The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Oxford, England: The Cochrane Collaboration, 2003.
60. Rust 2005 Rust OA, Atlas RO, Kimmel S, Roberts WE, Hess LW. Does the presence of a funnel increase the risk of adverse perinatal outcome in a patient with a short cervix?. American Journal of Obstetrics and Gynecology 2005;192(4):1060-6.
61. Silver 1999 Silver RI, Rodriguez R, Chang TS, Gearhart JP. In vitro fertilization is associated with an increased risk of hypospadias. Journal of Urology 1999;161(6):1954-7.
62. Stites 1983 Stites DP, Bugbee S, Siiteri PK. Differential action of progesterone and cortisol on lymphocyte and monocyte interaction during lymphocyte activation - relevance to immunosuppression in pregnancy. Journal of Reproductive Immunology 1983;5:215-28.
63. Szabo 1996 Szabo I, Szilagyi A. Management of threatened abortion. Early Pregnancy 1996;2(4):233-40.
64. Tang 2003 Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reproduction 2003;18(11):2315-8.
65. Temmerman 1992 Temmerman M, Lopita MI, Sanghvi HC, Sinei SK, Plummer FA, Piot P. The role of maternal syphilis, gonorrhoea and HIV-1 infection in spontaneous abortion. International Journal of Sexually Transmitted Diseases and AIDS 1992;3:418-22.
66. WHO 1992 World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Edition. Vol. 1, Geneva: World Health Organization, 1992.